- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02723461
Continuous Oxytocin Infusion Versus Pulsatile Intravenous Oxytocin for Augmentation of First Stage of Labor
Randomised Controlled Trial Comparing Continuous Intravenous Oxytocin Infusion With Pulsatile Administration of Intravenous Oxytocin for Augmentation of the First Stage of Labor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study population comprises120 cases with spontaneous onset of labor who are admitted to the labor ward at causalities of Ain shams university maternity hospital.
The required sample size has been calculated using the IBM© SamplePower© Software (IBM© Corp., Armonk, NY, USA). A previous study by Tribe et al., 2012 reported that the mean infusion to delivery time associated with continuous infusion of oxytocin was 7.17 hours with a 95% confidence interval (95% CI) of 6.58 to 7.77 hours versus 9.61 hours (95% CI, 8.95 to 10.27 hours) in association with pulsatile oxytocin. The sample size for either regimen in that study was 240 patients or 241 patients, respectively. From the study of Tribe et al. (2012), it could be estimated that the standard deviation (SD) for the infusion to delivery time was 4.66 hours or 5.23 hours for the continuous or pulsatile oxytocin regimen, respectively. This calculation is derived from solving any of the following equations for the SD given the mean, lower or upper 95% CI limit, and sample size:
Lower 95% CI limit = mean - (1.96 * SD / √n)..... Equation 1 Upper 95% CI limit = mean + (1.96 * SD / √n…..Equation 2 where SD is the standard deviation and n is the sample size (Chow et al., 2003).
So, it is estimated that a sample size of 66 patients in either study group (total, 132 patients) would achieve a power of 80% (type II error, 0.2) to detect a statistically significant difference between the two groups as regards the infusion to delivery time using a two-side unpaired Student t test with a confidence level of 95% (type I error, 0.05). the mean ± SD infusion to delivery time in both groups is assumed to be identical and to equal 9.61 ± 5.23 hours under the null hypothesis. Under the alternative hypothesis, the mean ± SD infusion to delivery time is assumed to equal 7.17 ± 4.66 hours in the continuous infusion group versus 9.61 ± 5.23 hours in the pulsatile group.
This sample size of 66 patients in each study group would have a power of 93% (type II error, 0.07) to detect a statistically significant difference between the two groups as regards the rate of successful induction of labor for a medium effect size (w) of 0.3 using a two-sided chi-squared test with a confidence level of 95% (type I error, 0.05). The effect size (w) is calculated as follows:
w =√(χ^2/N), where χ2 is the chi-squared statistic and N is the total sample size. (Chow et al., 2003).
Following admission, all patients will undergo complete clinical examination and detailed medical history will be obtained as follows:
A. Personal history. B. Obstetric history: where the gestational age will be calculated by the date of last menstrual period or by ultrasonography in unreliable dates.
C. Gynecological history.
Grouping:
The patients needing augmentation of first stage of labor will be divided equally into two groups:
Group 1 (study group ; 60 patients ) :
Patients at labor are given augmentation by oxytocin in pulsatile method
Group 2 (control group ;60 patients) :
Patients at labor are given augmentation by oxytocin in continuous method
Intervention:
Pulsatile group:
Pulsatile infusion protocol using a programmable syringe pump is applied .The pulsatile regime, oxytocin (Syntocinon,stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) will be doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
Continuous group :
Continuous group will be administrated oxytocin (Syntocinon,stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10minutes).
Then each patient will have case record form in which the following data will be recorded:
- Patient initials.
- Study number.
- Group.
- Parity.
- Gestatinal age ( first day of last menstrual period - early ultrasound).
- Rupture of membranes.
- Duration of rupture of membranes.
- Duration of first stage of labour.
- Duration of second stage of labour.
- Need for instrumental delivery.
- Need for Cesarean section.
- Adverse effect.
- Neonatal outcome.
- Maternal complications.
- Adverse effect related to oxytocin.
- Total dose of oxytocin infused.
- Previous complicated vaginal delivery.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Recruiting
- Ain Shams Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Women in labor (cervical dilatation 3-4 centimeters) who require augmentation of first stage of labor.
- Single viable fetus.
- Rupture of membranes before augmentation of labor.
- Cephalic presentation.
- Term pregnancy.
Exclusion Criteria:
- Malpresentation.
- Induction of labor by prostaglandins.
- Any uterine previous surgery.
- Fetal anomalies.
- Premature labor.
- Previous cesarean section.
- Any uterine anomalies.
- Multiple pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: pulsatile oxytocin
Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
|
Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Other Names:
|
Active Comparator: continuous oxytocin
Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
|
Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
duration of active phase of first stage of labor
Time Frame: 24 hours
|
The time in hours from start of infusion of pulsatile oxytocin at onset of established labor (cervical dilatation 3-4 cm ) to the end of first stage of labour (cervical dilatation 10 cm)
|
24 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- pulsatile oxytocin
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Failed Induction (of Labor) by Oxytocin
-
Zeynep Kamil Maternity and Pediatric Research and...CompletedOxytocin | Induction of LaborTurkey
-
The First Affiliated Hospital with Nanjing Medical...RecruitingPrelabor Rupture of Membranes | Failed Induction (of Labor) by Oxytocin | Failed Trial of Labor, Unspecified, With Delivery | Failed VBAC (Vaginal Birth After Caesarean)China
-
Seoul National University HospitalCompletedFailed Induction of LaborKorea, Republic of
-
Ain Shams UniversityCompleted
-
Kasr El Aini HospitalCompleted
-
Seoul National University HospitalCompletedFailed Induction of LaborKorea, Republic of
-
Seoul National University HospitalCompletedFailed Induction of LaborKorea, Republic of
-
Seoul National University HospitalCompletedFailed Induction of LaborKorea, Republic of
-
Seoul National University HospitalCompletedFailed Induction of LaborKorea, Republic of
Clinical Trials on Pulsatile Oxytocin
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingThrombocytopenia | Surgery | Acute Kidney Injury | HemolysisUnited States
-
US Department of Veterans AffairsCompleted
-
University Hospital, Clermont-FerrandSTENDO, 17 rue du port 27400 LOUVIERSCompleted
-
Charite University, Berlin, GermanyHeVaTech GmbHCompleted
-
Assistance Publique - Hôpitaux de ParisXenios AGRecruitingAcute Respiratory Distress Syndrome | Pulmonary Disease | Extracorporeal CO2 Removal | Chronic Obstructive Pulmonary Disease ExacerbationFrance
-
University of CatanzaroCompleted
-
Kinamed IncorporatedUS Department of Veterans AffairsCompletedPostoperative Complications | Memory DisordersUnited States
-
University of Sao Paulo General HospitalUnknown
-
Hospices Civils de LyonCompletedPulsatile Perfusion Preservation in Kidney Transplantation From Expanded Criteria Donors (IMPULSION)Chronic Renal FailureFrance
-
Florida Atlantic UniversityAdvanced Diabetes Treatment Centers; Global InfusionsTerminatedDiabetes Mellitus, With ComplicationsUnited States